Loading...
Loading...
By Sofía Garduño - Thu, 11/27/2025 - 09:50
This week, Mexico saw key trade news, trial results from Novo Nordisk, Eli Lilly’s valuation milestone, and new actions to improve care.
https://mexicobusiness.news/tag/semaglutide
More Health
By Sofía Garduño - Mon, 11/24/2025 - 14:24
Novo Nordisk’s phase 3 trials of oral semaglutide in early Alzheimer’s failed to meet primary endpoints.
By MBN Staff - Thu, 09/18/2025 - 09:13
Orforglipron lowered A1C and body weight more than oral semaglutide in a 52-week Phase 3 trial for type 2 diabetes, reports Eli Lilly.
By Sofía Garduño - Mon, 08/18/2025 - 09:14
The US FDA approves Wegovy to treat adults with MASH and moderate to advanced liver fibrosis, excluding cirrhosis.
By MBN Staff - Fri, 05/02/2025 - 08:22
Galmed signs a global deal to develop a sublingual Semaglutide formulation, targeting Mexico and international markets.
By Sofía Garduño - Thu, 03/06/2025 - 18:43
This week, Mexico and PAHO discussed plans to strengthen regional health systems. Meanwhile, WHO issued 2025-2026 flu vaccine recommendations.
By MBN Staff - Fri, 02/28/2025 - 16:18
Novo Nordisk to launch semaglutide 2.4mg in Mexico for weight management. The drug is designed to aid obesity and overweight treatment.
By Sofía Garduño - Mon, 02/24/2025 - 11:27
The FDA confirms that US supply of Wegovy and Ozempic now meets or exceeds demand, following Novo Nordisk's US$6.5 billion investment.
By MBN Staff - Tue, 12/03/2024 - 10:37
Canada approves Novo Nordisk’s Wegovy to reduce heart attack risk in obese adults with cardiovascular disease.
By Sofía Garduño - Thu, 11/14/2024 - 08:12
Semaglutide and liraglutide, initially developed for diabetes and obesity, may offer a promising new approach for treating alcohol use disorder.
